Strata Oncology, Inc., a leading player in the precision oncology sector, is headquartered in the United States. Founded in 2012, the company has rapidly established itself as a pioneer in molecular profiling and genomic testing, focusing on advanced cancer diagnostics. Strata's innovative approach centres on its proprietary StrataNGS™ platform, which enables comprehensive genomic analysis to identify actionable mutations in cancer patients, setting it apart in the competitive landscape. With a strong presence across major operational regions in North America, Strata Oncology has achieved significant milestones, including partnerships with prominent healthcare institutions and biopharmaceutical companies. The company’s commitment to improving patient outcomes through personalised medicine has solidified its market position, making it a trusted name in the oncology industry.
How does Strata Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Strata Oncology, Inc.'s score of 18 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Strata Oncology, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Strata Oncology may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it remains essential for organisations like Strata Oncology to consider developing and communicating their climate strategies to align with global efforts in reducing greenhouse gas emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Strata Oncology, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
